Literature DB >> 31649053

Risk of metastatic pheochromocytoma and paraganglioma in SDHx mutation carriers: a systematic review and updated meta-analysis.

Hansong Lee1, Seongdo Jeong1, Yeuni Yu1, Junho Kang1, Hokeun Sun2, Je-Keun Rhee3, Yun Hak Kim4.   

Abstract

BACKGROUND: Pheochromocytoma and paraganglioma (PPGL) are tumours that arise from chromaffin cells. Some genetic mutations influence PPGL, among which, those in genes encoding subunits of succinate dehydrogenase (SDHA, SDHB, SDHC and SDHD) and assembly factor (SDHAF2) are the most relevant. However, the risk of metastasis posed by these mutations is not reported except for SDHB and SDHD mutations. This study aimed to update the metastatic risks, considering prevalence and incidence of each SDHx mutation, which were dealt formerly all together.
METHODS: We searched EMBASE and MEDLINE and selected 27 articles. The patients included in the studies were divided into three groups depending on the presence of PPGL. We checked the heterogeneity between studies and performed a meta-analysis using Hartung-Knapp-Sidik-Jonkman method based on a random effect model.
RESULTS: The highest PPGL prevalence was for SDHB mutation, ranging from 23% to 31%, and for SDHC mutation (23%), followed by that for SDHA mutation (16%). The lowest prevalence was for SDHD mutation, ranging from 6% to 8%. SDHAF2 mutation showed no metastatic events. The PPGL incidence showed a tendency similar to that of its prevalence with the highest risk of metastasis posed by SDHB mutation (12%-41%) and the lowest risk by SDHD mutation (~4%).
CONCLUSION: There was no integrated evidence of how SDHx mutations are related to metastatic PPGL. However, these findings suggest that SDHA, SDHB and SDHC mutations are highly associated and should be tested as indicators of metastasis in patients with PPGL. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  SDHx mutation; genetic epidemiology; genetic screening/counselling; neuro endocrinology; pheochromocytoma and paraganglioma

Mesh:

Substances:

Year:  2019        PMID: 31649053     DOI: 10.1136/jmedgenet-2019-106324

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  6 in total

Review 1.  What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas?

Authors:  Thomas G Papathomas; Diederik P D Suurd; Alfred K Lam; Ronald R de Krijger; Karel Pacak; Arthur S Tischler; Menno R Vriens
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

2.  Local Tumor Behavior Associated With Survival Among Patients With Paraganglioma of the Head and Neck.

Authors:  Randall J Harley; Jason H Lee; Benjamin T Ostrander; Andrey Finegersh; Tammy B Pham; Kareem O Tawfik; Yin Ren; Farhoud Faraji; Rick A Friedman
Journal:  OTO Open       Date:  2022-03-31

3.  GIPC2 is an endocrine-specific tumor suppressor gene for both sporadic and hereditary tumors of RET- and SDHB-, but not VHL-associated clusters of pheochromocytoma/paraganglioma.

Authors:  Yeqing Dong; Yongsheng Huang; Chengyan Fan; Liang Wang; Ran Zhang; Wenhua Li; Zhengguang Guo; Dong Wang; Zhi Zheng
Journal:  Cell Death Dis       Date:  2021-05-04       Impact factor: 8.469

4.  Diagnosis for Pheochromocytoma and Paraganglioma: A Joint Position Statement of the Korean Pheochromocytoma and Paraganglioma Task Force.

Authors:  Eu Jeong Ku; Kyoung Jin Kim; Jung Hee Kim; Mi Kyung Kim; Chang Ho Ahn; Kyung Ae Lee; Seung Hun Lee; You-Bin Lee; Kyeong Hye Park; Yun Mi Choi; Namki Hong; A Ram Hong; Sang-Wook Kang; Byung Kwan Park; Moon-Woo Seong; Myungshin Kim; Kyeong Cheon Jung; Chan Kwon Jung; Young Seok Cho; Jin Chul Paeng; Jae Hyeon Kim; Ohk-Hyun Ryu; Yumie Rhee; Chong Hwa Kim; Eun Jig Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2021-04-06

5.  Impact of gender on the prognosis of carotid body tumor after surgical resection.

Authors:  Huanrui Hu; Yuwei Xiang; Bin Huang; Ding Yuan; Yi Yang; Jichun Zhao
Journal:  J Otolaryngol Head Neck Surg       Date:  2021-09-27

Review 6.  Personalized Management of Pheochromocytoma and Paraganglioma.

Authors:  Svenja Nölting; Nicole Bechmann; David Taieb; Felix Beuschlein; Martin Fassnacht; Matthias Kroiss; Graeme Eisenhofer; Ashley Grossman; Karel Pacak
Journal:  Endocr Rev       Date:  2022-03-09       Impact factor: 19.871

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.